We have also shed light on its mechanism of action as we found that the treatment with the bi-specific tribody induces activation of T cells against cancer cells and ultimately leads to IFNγ secretion, which in turn can induce the expression of PD-L1 on tumor cells with a possible negative feedback mechanism, thus allowing the tumor cells to escape the immune system. The gene discussed is IFNG; the disease is cancer.